Loading stock data…
$1.17+0.05 (+4.46%)
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States.
HCW Biologics Inc. in the Healthcare sector is trading at $1.17 with a market capitalization of $3M. Wall Street consensus targets $48.00 (1 analysts), implying a +4002.6% move over the next 12 months. The stock is currently near its 52-week low of $1.09, remaining 72.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $135,568↓ | $6.54M↑ | $27,010↑ | $15,606↑ | $6,550 |
| Gross Profit | -$93,887↓ | $6.53M↑ | $5,401↑ | $3,121↑ | $1,310 |
| Operating Income | -$3.15M↓ | $3.25M↑ | -$2.95M↑ | -$3.28M↑ | -$3.36M |
| Net Income | -$5.22M↓ | $3.47M↑ | $719,232↑ | -$4.55M↓ | -$1.93M |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-v...